Topline Data for Oral Semaglutide in PIONEER 6 Outcomes Trial Topline Data for Oral Semaglutide in PIONEER 6 Outcomes Trial

An investigational oral form of the GLP-1 agonist semaglutide for type 2 diabetes has demonstrated safety for the overall MACE endpoint in the cardiovascular outcomes trial PIONEER-6.Medscape Medical News

Source: Medscape Diabetes Headlines - November 26, 2018 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news